linjc16/ctgov huggingface dataset:
Study of XL820 in Adults With Solid Tumors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.

Official Title
-----------------
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Drug: XL820


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Advanced solid tumor Cancer for which standard therapies do not exist or are no longer effective Life expectancy of > 3 months Adequate bone marrow, liver, and kidney function Willing to use accepted method of contraception during the course of the study Negative pregnancy test (females) Written informed consent Exclusion Criteria: Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy) Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment Investigational drug within 30 days of the start of treatment Subjects with known brain metastasis Uncontrolled medical disorder such as infection or cardiovascular disease Subjects known to be HIV positive Pregnant or breastfeeding women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: XL820|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study of the Geometry of the Immature Human Femur Before the Age of 3 Years From Data Measured on CT Scan

Study Overview
=================
Brief Summary
-----------------
Childhood fractures are the second most common presentation of abuse. The target population for screening for these injuries is children under the age of three who are unable to express themselves about the circumstances of the trauma, hence the need to develop a validated model to predict the outcome of trauma as well as the origin of a fracture. Few morphological data are available in the literature for the femur concerning the period of rapid growth between 0 and 3 years of age.

Official Title
-----------------
Study of the Geometry of the Immature Human Femur Before the Age of 3 Years From Data Measured on CT Scan

Conditions
-----------------
Femur Fracture, Childhood

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Minor patient who died before the age of 3 years Whole body CT imaging performed post mortem on judicial requisition in the framework of a forensic procedure Absence of refusal in the medical file by the holders of parental authority concerning the re-use of their child's data for the purposes of this research Exclusion criteria: Refusal manifested in the medical record by parental authority holders regarding the reuse of their child's data for the purpose of this research, Femur not fully assessable on imaging acquisition

Ages Eligible for Study
-----------------
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To retrospectively characterize the variations in femur morphology during growth in a target pediatric population aged 0 to 3 years | To retrospectively characterize the variations in femur morphology during growth in a target pediatric population aged 0 to 3 years with the aim of later developing a numerical model to study fracture mechanisms for forensic applications | Files analysed retrospectively from January 01, 2015 to February 29, 2020 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Femur Fracture, Childhood
Decreased Consumption of Blood Components During Cardiac Surgery Procedures: Causes and Effects.

Study Overview
=================
Brief Summary
-----------------
There is a decrease in the amount of blood components used during cardiac surgery in the last four years. As the hemovigilance team of the investigators' Hospital the investigators want to find out the causes and effects of this decrease.

Official Title
-----------------
Decreased Consumption of Blood Components During Cardiac Surgery Procedures: Causes and Effects.

Conditions
-----------------
Blood Safety, Blood Transfusion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient underwent cardiac surgery between 2010 and 2014 in UZ Leuven Exclusion Criteria: patient without cardiac surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| amount of blood use during Cardiac surgery |  | 5years |
Influence of Transcranial Direct Current Stimulation on Cortical Plasticity in Concussed Athletes

Study Overview
=================
Brief Summary
-----------------
Concussed athlethes have discrete decreased abilities in motor learning. Recent research could further show, that cortical plasticity, as measured by transcranial magnetic stimulation (TMS) is reduced. This is possibly due to an increased GABAergic activity, what have been found in concussed athletes by paired pulse protocols in TMS. GABAergic acitivty can be modulated by transcranial direct current stimulation (tDCS) in a polar-specific manner: anodal tDCS was able to decrease GABA, whereas cathodal tDCS increased tDCS. Our study aimes to assess the influence of anodal tDCS on cortical plsticity in concussed athlethes. We hypothesize, that anodal tDCS is able to increase cortical plsticity in concussed athlethes.

Official Title
-----------------
Influence of Anodal Transcranial Direct Current Stimulation on Cortical Plasticity in Concussed Athletes and Healthy Volunteers

Conditions
-----------------
Concussed Athletes, Healthy Controls

Intervention / Treatment
-----------------
* Behavioral: tDCS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: history of at least 2 sports concussion age 18 - 50 years Exclusion Criteria: structural deficit on cerebral MRI Epilepsy neurological disorder intake of CNS-active drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Concussed athletes<br> | Behavioral: tDCS<br> <br> |
| Other: Healthy controls<br> | Behavioral: tDCS<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of cortical plasticity after anodal tDCS in concussed athletes |  |  |
Observational Study About Patients Diagnosed With NAFLD

Study Overview
=================
Brief Summary
-----------------
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome. The largest study to date using magnetic resonance spectroscopy to quantify liver triglyceride (TG) content showed that approximately 33% of individuals have hepatic steatosis. NAFLD encompasses a continuum of histological findings that starts with steatosis that can progress to nonalcoholic steatohepatitis (NASH), which is characterized by inflammation and cell death, and eventually cirrhosis. Given the large number of individuals afflicted with this condition, there is a clear need to develop effective and safe therapies to treat NAFLD.

Detailed Description
-----------------
Patients with NAFLD were recruited in the current study and divided into NAFLD group, and NASH group. The researchers will collect various clinical examination indexes of the subjects in the process of diagnosis and treatment, including but not limited to ALT, AST, TG, TC, etc. Characteristic and prognosis of patients will be recorded. The serum, feces, urine and liver (if necessary) samples of all subjects will be taken after enrollment and stored for probably testing in the future. This study has no additional intervention and treatment for subjects.

Official Title
-----------------
Study on the Characteristic, Therapy and Prognosis of Patients With Nonalcoholic Fatty Liver Disease

Conditions
-----------------
Nonalcoholic Fatty Liver Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. patients diagnosed with nonalcoholic fatty liver disease Exclusion Criteria: patients suspected of excessive alcohol consumption malignant tumors, dementia, active tuberculosis, AIDS, organ failure, pregnancy or breastfeeding, etc cannot cooperate with the investigation incomplete data such as HBV serological results and abdominal ultrasound results patients who refuse to sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients diagnosed with NAFLD<br>All subjects will receive the currently recognized routine test of NAFLD according to their disease and no additional intervention and treatment will be added for subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BMI | BMI stands for body mass index. This is the ratio of a person's height to their weight. | 3 weeks | 
| alcohol intake | alcohol consumption every week | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nonalcoholic Fatty Liver Disease
Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to compare the Efficacy and Safety of Tiropramide HCl and Octylonium bromide in the Treatment of Irritable Bowel Syndrome.

Official Title
-----------------
Comparative and Analytical Study for Effectiveness and Safety of Tiropramide HCl and Octylonium Bromide in the Treatment of Irritable Bowel Syndrome: Mullticenter, Randomized, Double Blind, Active Controlled Study

Conditions
-----------------
Irritable Bowel Syndrome

Intervention / Treatment
-----------------
* Drug: Tiropramide HCl 100mg
* Drug: Octylonium bromide 20mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (aged 20-75 years) Patients who had been suffered from IBS as defined by Rome III criteria Patients who had abdominal pain at least 2 days/week, during the run-in period of 2 weeks Exclusion Criteria: Patients with known intolerance to tiropramide or octylonium Patients with uncontrolled diabetes, uncontrolled hypertension or thyroid dysfunction Patients who had the history of cancer [However, patients with cancer other than gastrointerstinal cancer, who have not recurr within 5 years after treatment were possible for enrollment] Patients with hepatic or renal dysfunction Patients with lactose intorelance

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tiropramide HCl<br> | Drug: Tiropramide HCl 100mg<br> <br> |
| Active Comparator: Octylonium bromide<br> | Drug: Octylonium bromide 20mg<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of abdominal pain VAS scores from baseline to week 4 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of abdominal pain VAS scores from baseline to week 2 |  |  | 
| Change of abdominal discomfort VAS scores from baseline to week 2 and 4 |  |  |
The Effect of Frequent Self Measurements of Blood Pressure on the Control of Hypertension

Study Overview
=================
Brief Summary
-----------------
Despite knowledge regarding the importance of controlling patients' blood pressure (BP) only 30% of treated patients achieve BP goals. Our objective was to determine the effect of frequent self measurements of BP in the patients' natural environment as a mean to improve BP control. Our hypothesis was that frequent measurements of BP will reduce mean BP levels.

Official Title
-----------------
The Effect of Frequent Self Measurements of Blood Pressure on the Control of Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Device: Portable blood pressure wrist manometer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signing an informed consent form Having a diagnosis of hypertension for more than one year according to patients'records. receiving at least one medication for hypertension A reasonable understanding of Hebrew An ambulatory state enabling regular visits to a primary physician in the community and self-measurement of hypertension using the electronic device Exclusion Criteria: Lack of willingness to participate in the study.Known arrhythmia Malignant disease Poor understanding of Hebrew

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Portable blood pressure wrist manometer|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Meam blood pressure |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction |  |  | 
| Quality of life |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
24 hour ambulatory blood pressure measurement, Mean blood pressure, Wrist manometer, Frequent measurement
Haptoglobin and Preeclampsia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to show that a certain protein called haptoglobin protects against preeclampsia which is a common pregnancy complication.

Conditions
-----------------
Preeclampsia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all women Exclusion Criteria: women with hypertension
Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy control<br>240 female subjects without preeclampsia | |
| preeclampsia<br>120 female subjects with preeclampsia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Predictive Factors of Graft Detachment Following Dmek

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to identify the predictive factors of graft detachment after Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. This retrospective study was conducted on patients aged 18 years, with Fuchs' dystrophy (FECD) or pseudophakic bullous keratopathy (PBK), who were scheduled for DMEK or triple-DMEK (combined phacoemulsification and DMEK surgery). Patients with a history of surgery other than cataract surgery were excluded. The study was conducted between 2014 and 2022 and follow-up was for 3 months. The characteristics of patients with and without graft detachment following surgery were compared using logistic regression.

Official Title
-----------------
Predictive Factors of Graft Detachment Following Dmek: Retrospective Study About 170 Cases

Conditions
-----------------
Fuchs' Endothelial Corneal Dystrophy, Descemet Membrane Endothelial Keratoplasty, Pseudophakic Bullous Keratopathy, Graft Detachment

Intervention / Treatment
-----------------
* Procedure: Descemet Membrane Endothelial Keratoplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years of age with DMEK surgery Exclusion Criteria: all associated eye surgery other than cataract surgery all existing anterior segment anomalies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| DMEK-operated eyes without graft detachment<br>Eyes operated with DMEK without graft detachment | Procedure: Descemet Membrane Endothelial Keratoplasty<br>* DMEK-operated eyes<br>|
| DMEK-operated with graft detachment<br>Eyes operated with DMEK with graft detachment | Procedure: Descemet Membrane Endothelial Keratoplasty<br>* DMEK-operated eyes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Appearence of the graft on anterior segment optical coherence tomography (AS OCT) examination | clinical examination and anterior segment optical coherence tomography (AS OCT) examination (appearence of the graft) | up to 3 months after surgery |
Prolonged Exposure Versus Treatment as Usual in Chronic Posttraumatic Stress Disorder Combat and Terror Related Patients

Study Overview
=================
Brief Summary
-----------------
Assessing the efficacy of Posttraumatic Stress Disorder (PE) treatment for chronic Posttraumatic Stress Disorder (PTSD)

Conditions
-----------------
Posttraumatic Stress Disorder

Intervention / Treatment
-----------------
* Behavioral: Prolonged Exposure (PE) therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PTSD Exclusion Criteria: Psychotic symptoms Dissociation Drug or Alcohol dependence

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Prolonged Exposure (PE) therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Opioid Maintenance Medications Comparison Study

Study Overview
=================
Brief Summary
-----------------
A 17 week, double-blind, randomized, parallel group, four arm design outpatient study comparing LAAM, buprenorphine and two dose levels of methadone for the treatment of opioid dependence.

Conditions
-----------------
Opioid Dependence

Intervention / Treatment
-----------------
* Drug: LAAM. buprenorphine and methadone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion age 21 to 55 years diagnosis of opioid dependence by criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) evidence of recent opioid use on toxicologic screening Exclusion serious medical or psychiatric illness requiring long-term medication positive pregnancy test

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: LAAM. buprenorphine and methadone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study retention |  |  | 
| Drug use |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety |  |  |